Foresee Pharmaceuticals Co., Ltd.
Taipei ExchangeTotal Valuation
Foresee Pharmaceuticals Co., Ltd. carries a market capitalization of 13.38B, placing it among publicly traded companies globally. Its enterprise value stands at 11.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 13.38B |
| Enterprise Value | 11.95B |
Share Statistics
Foresee Pharmaceuticals Co., Ltd. currently has 157.54M shares outstanding.
| Shares Outstanding | 157.54M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 28.81, and the price-to-book ratio stands at -2.43.
| PE Ratio | N/A |
| PS Ratio | 28.81 |
| PB Ratio | -2.43 |
| P/TBV Ratio | 15.18 |
| P/FCF Ratio | -15.03 |
| P/OCF Ratio | -14.75 |
Enterprise Valuation
| EV / Sales | 27.72 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Foresee Pharmaceuticals Co., Ltd. maintains a current ratio of 3.44, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.93, indicating elevated leverage, while an interest coverage ratio of -154.90 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.44 |
| Quick Ratio | 2.45 |
| Debt / Equity | 24.93 |
| Debt / EBITDA | -0.27 |
| Interest Coverage | -154.90 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -50.91 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.83 |
Taxes
| Income Tax | 24.95M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Foresee Pharmaceuticals Co., Ltd.'s stock has gained approximately 30.01531% over the past 52 weeks. The 50-day moving average sits at 79.44, while the 200-day moving average is 80.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | 30.01531% |
| 50-Day Moving Average | 79.44 |
| 200-Day Moving Average | 80.01 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Foresee Pharmaceuticals Co., Ltd. generated 431.27M in revenue and converted that into -883.15M in net income, yielding earnings per share of -5.73. EBITDA reached -862.32M, while operating income came in at -862.32M.
| Revenue | 431.27M |
| Gross Profit | 294.22M |
| Operating Income | -862.32M |
| Pretax Income | -858.20M |
| Net Income | -883.15M |
| EBITDA | -862.32M |
| EBIT | -862.32M |
| Earnings Per Share (EPS) | -5.73 |
Balance Sheet
Foresee Pharmaceuticals Co., Ltd. holds 700.22M in cash and equivalents against 231.74M in total debt, resulting in a net debt position of -282.52M. Total book value stands at -5.12B, with working capital of 699.41M providing operational flexibility.
| Cash & Cash Equivalents | 700.22M |
| Total Debt | 231.74M |
| Net Debt | -282.52M |
| Equity (Book Value) | -5.12B |
| Book Value Per Share | -33.21 |
| Working Capital | 699.41M |
Cash Flow
Foresee Pharmaceuticals Co., Ltd. produced -842.23M in operating cash flow over the past twelve months. After subtracting -15.50M in capital expenditures, free cash flow totaled -857.73M - equivalent to -5.56 per share.
| Operating Cash Flow | -842.23M |
| Capital Expenditures | -15.50M |
| Free Cash Flow | -857.73M |
| FCF Per Share | -5.56 |
Margins
Foresee Pharmaceuticals Co., Ltd. operates with a gross margin of 68.22, reflecting its pricing power and cost economics. The operating margin of -199.95 and net profit margin of -204.78 provide insight into operational efficiency.
| Gross Margin | 68.22 |
| Operating Margin | -199.95 |
| Pretax Margin | -198.99 |
| Profit Margin | -204.78 |
| EBITDA Margin | -199.95 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1.08 |
| FCF Yield | -6.65 |
Stock Splits
Foresee Pharmaceuticals Co., Ltd.'s most recent stock split took place on June 1, 2023 with a 1000:1011 split ratio.
| Last Split Date | 6/1/2023 |
| Split Ratio | 1000:1011 |
Scores
Foresee Pharmaceuticals Co., Ltd. posts an Altman Z-Score of 10.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.45 |